Property:Outcome name
This is a property of type Text.
The allowed values for this property are:
- Additional medication
- Anorexia/Cachexia
- Antibodies
- Anxiety
- Appetite
- Arterial inflow
- BMD (Bone Mineral Density)
- Body composition
- Carnitine level
- Carotenoid concentration
- Cerebral oedema
- CINV (Chemotherapy-Induced Nausea and Vomiting)
- Cognitive functioning
- Cognitive impairment
- Depression
- Dermatitis
- DFS (Disease-Free Survival)
- Diarrhoe
- Distress
- Dysgeusia
- Ejection fraction
- Erectile dysfunction
- Erythema
- Esophagitis
- Fatigue
- Fever
- Fibrosis
- Folic acid level
- Functionality
- Haematological indices
- Haematological toxicity
- Hand-foot syndrome
- Hand grip strength
- Hormone level
- Incidence of acute GVHD (Graft-Versus-Host Disease)
- Infection
- Interaction with cancer treatment
- Ileus (intestinal obstruction)
- Laboratory parameters
- Length of hospital stay
- Lymphedema
- Menopausal symptoms
- Mental status/ function
- Mood/Affect
- Mortality rate
- Mucositis
- Musculoskeletal symptoms
- Nausea
- Nausea and Vomiting
- Nerve conduction velocity
- Neurotoxicity
- Neutropenia
- Non-haematological indices
- Nutrition status
- Objective signs and subjective symptoms
- Oral ulcus
- OS (Overall Survival)
- Ototoxicity
- Pain
- PD (Pharmacodynamics)
- Performance Status
- Peripheral neuropathy
- PFS (Progression-Free Survival)
- Pharyngitis
- Physical functioning
- PK (Pharmacokinetics)
- Postoperative morbidity/ complications
- PSA level (Prostate-Specific Antigen)
- Quality of life
- Recurrence rate
- REE (Resting Energy Expenditure)
- Relaxation
- RFS (Recurrence-Free Survival)
- Salivary gland function
- Seroconversion
- Selenium level
- Sleep
- Stomatitis
- Stress
- Symptom load
- Taste alteration
- Tea polyphenol uptake
- Thromboembolic event rates
- Toxicity
- Treatment interruption
- Tumor progression
- Tumor response
- Vaginal atrophy
- Vitamin A level
- Vitamin B6 level
- Vitamin B12 level
- Vitamin B17 level
- Vitamin C level
- Vitamin D level
- Vitamin E level
- Vomiting
- Weight
- Well-being
- Wound healing
- Wound odour
- Xerostomia
- Zinc level
- Unspecified effects
- NI
- ?
J
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Appetite +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Recurrence rate +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Tumor progression +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Vitamin A level +
K
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Selenium level +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
OS (Overall Survival) +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Toxicity +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
DFS (Disease-Free Survival) +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Lymphedema +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Lymphedema +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Lymphedema +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
Vaginal atrophy +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Tumor response +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Tumor response +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Fatigue +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Hand grip strength +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Musculoskeletal symptoms +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
Vitamin D level +
Showing 1 related entity.
{ "type": "PROPERTY_CONSTRAINT_SCHEMA", "constraints": { "type_constraint": "_txt", "allowed_values": [ "Anorexia/Cachexia", "Anxiety", "Appetite", "Cerebral oedema", "Cognitive functioning", "Cognitive impairment", "Depression", "Dermatitis", "Distress", "Dysgeusia", "Ejection fraction", "Erectile dysfunction", "Fatigue", "Haematological toxicity", "Hand-foot syndrome", "Ileus (intestinal obstruction)", "Lymphedema", "Menopausal symptoms", "Mood/Affect", "Mucositis", "Nausea", "Nausea and Vomiting", "Neutropenia", "Ototoxicity", "Pain", "Quality of life", "Recurrence rate", "Relaxation", "Stress", "Toxicity", "Vaginal atrophy", "Vomiting", "Weight", "Well-being", "Wound healing", "Xerostomia", "?", "NI", "Esophagitis", "Seroconversion", "Antibodies", "Carnitine level", "Folic acid level", "Haematological indices", "Incidence of acute GVHD (Graft-Versus-Host Disease)", "Length of hospital stay", "Mortality rate", "Non-haematological indices", "Performance Status", "Selenium level", "Tumor response", "Vitamin A level", "Vitamin B6 level", "Vitamin B12 level", "Vitamin B17 level", "Vitamin C level", "Vitamin D level", "Vitamin E level", "Zinc level", "OS (Overall Survival)", "Body composition", "Diarrhoe", "Nutrition status", "PSA level (Prostate-Specific Antigen)", "Taste alteration", "Tumor progression", "DFS (Disease-Free Survival)", "PFS (Progression-Free Survival)", "RFS (Recurrence-Free Survival)", "Carotenoid concentration", "Pharyngitis", "CINV (Chemotherapy-Induced Nausea and Vomiting)", "Fibrosis", "Functionality", "Hand grip strength", "Hormone level", "Musculoskeletal symptoms", "Objective signs and subjective symptoms", "Salivary gland function", "Thromboembolic event rates", "Wound odour", "BMD (Bone Mineral Density)", "PD (Pharmacodynamics)", "Sleep", "Tea polyphenol uptake", "Unspecified effects", "Peripheral neuropathy", "PK (Pharmacokinetics)", "Arterial inflow", "Erythema", "Laboratory parameters", "Mental status/ function", "Neurotoxicity", "Oral ulcus", "Physical functioning", "Additional medication", "Interaction with cancer treatment", "REE (Resting Energy Expenditure)", "Treatment interruption", "Fever", "Infection", "Nerve conduction velocity", "Postoperative morbidity/ complications", "Stomatitis", "Symptom load" ] } }